SPECTRUMEDIX CORP
NT 10-Q, 1999-11-15
LABORATORY ANALYTICAL INSTRUMENTS
Previous: ALEXANDRIA REAL ESTATE EQUITIES INC, 10-Q, 1999-11-15
Next: FIRSTBANK CORP/ID, 10QSB, 1999-11-15



<PAGE>

                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                  FORM 12b-25

                                                Commission File Number 000-09428

                          NOTIFICATION OF LATE FILING

     (Check One):  [_] Form 10-K   [_] Form 11-K   [_] Form 20-F   [X] Form 10-Q

[_] Form N-SAR

For Period Ended:  September 30, 1999
                  --------------------------------------------------------------

[_] Transition Report on Form 10-K     [_] Transition Report on Form 10-Q

[_] Transition Report on Form 20-F     [_] Transition Report on Form N-SAR

[_] Transition Report on Form 11-K

For the Transition Period Ended:
                                 -----------------------------------------------

    Read attached instruction sheet before preparing form. Please print or type.

    Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.

    If the notification relates to a portion of the filing checked above,
identify item(s) to which the notification relates:
                                                    ----------------------------

- --------------------------------------------------------------------------------
<PAGE>

                        Part I. Registrant Information

Full name of registrant  SpectruMedix Corporation
                        --------------------------------------------------------

Former name if applicable


- --------------------------------------------------------------------------------

Address of principal executive office (Street and number)

 2124 Old Gatesburg Road
- --------------------------------------------------------------------------------

City, State and Zip Code  State College, Pennsylvania 16803
                         -------------------------------------------------------


                        Part II. Rule 12b-25(b) and (c)

    If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check appropriate box.)

[X] (a) The reasons described in reasonable detail in Part III of this form
    could not be eliminated without unreasonable effort or expense;

[X] (b) The subject annual report, semi-annual report, transition report on Form
    10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or
    before 15th calendar day following the prescribed due date; or the subject
    quarterly report or transition report on Form 10-Q, or portion thereof will
    be filed on or before the fifth calendar day following the prescribed due
    date; and

[_] (c) The accountant's statement or other exhibit required by Rule 12b-25(c)
    has been attached if applicable.


                              Part III. Narrative

    State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F,
10-Q, N-SAR or the transition report portion thereof could not be filed within
the prescribed time period. (Attach extra sheets if needed).

        SpectruMedix Corporation, a Delaware corporation (the "Registrant"),
    recently filed its Quarterly Report on Form 10-Q for its fiscal quarter
    ended June 30, 1999, and the preparation of the Quarterly Report of Form
    10-Q was delayed until completion of such report.


                          Part IV. Other Information

    (1) Name and telephone number of person to contact in regard to this
notification.

    Karl Fazler                                       (814) 867-7600
- --------------------------------------------------------------------------------
      (Name)                                  (Area Code) (Telephone Number)

    (2) Have all other periodic reports required under Sections 13 and 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).
                                                              [X] Yes   [_] No

                                       2.
<PAGE>

    (3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?

                                                              [_] Yes   [X] No

    If so: attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.

 SpectruMedix Corporation
- --------------------------------------------------------------------------------
                 (Name of registrant as specified in charter)

Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.

Date:  November 12, 1999        By: /s/ Joseph K. Adlerstein
      -----------------------       --------------------------------------------
                                    Name:  Joseph K. Adlerstein
                                    Title: President and Chief Executive Officer

                                       3.


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission